kinder and gentler next-generation ADCs
About Kivu Bioscience
As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept.
Guided by rigorous science and a commitment to addressing unmet medical needs, our experienced team collaborates with global partners and key opinion leaders to accelerate the delivery of life changing antibody-drug conjugates (ADCs) that aim to conquer cancer.
Mission
We are inspired by patients and fueled by data to accelerate the development of novel cancer medicines.
Vision
To conquer cancer and deliver transformative ADCs that allow our patients to live longer and thrive.
Science
At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments. Utilizing Synaffix‘s site-specific conjugation platform, including the cutting-edge GlycoConnect™ technology, Kivu’s proprietary approach creates highly stable ADCs with optimized linker and payload combinations, designed to maximize therapeutic efficacy while minimizing off-tumor toxicity. By targeting aspargine-297, GlycoConnect™ produces a clean, highly homogenous product, offering a clear manufacturing advantage over other conjugation technologies. With state-of-the-art innovations in conjugation and payload delivery, we are shaping the future of targeted oncology therapies with a commitment to improving patient outcomes and treatment tolerability.
Kivu programs employ three technology pillars to deliver best-in-class ADCs by enhancing homogeneity, stability and potency.
Technology Pillars
Homogeneity
Stability
A hydrophilic linker increases polarity which reduces payload hydrophobicity and aggregation, resulting in improved payload retention. This enhancement positively impacts both manufacturability and efficacy by increasing ADC stability. Enhanced plasma stability further reduces off-target side effects, improving the safety profile for patients.
Potency
We utilize proprietary, clinically validated payloads with higher potency compared to previous payloads in the same class. These payloads demonstrate high permeability, bystander killing capability, and resistance to drug efflux transporters, maximizing therapeutic impact within tumor cells.
Pipeline
Target
Indication
Development Candidate
IND-Enabling
Phase 1
KIVU-107
Target:
Indication:
Candidate
IND-Enabling
Phase 1
KIVU-305
Target:
Indication:
Candidate
IND-Enabling
Phase 1
KIVU-495
Target:
Indication:
Candidate
IND-Enabling
Phase 1
KIVU-202
Target:
Indication:
Candidate
IND-Enabling
Phase 1
Who we are
Our team is driven by a passion for innovation and collaboration, working together to bring life-changing cancer treatments to the world.
Team
Board of Directors
Careers
A Culture of Belonging
Kivu Bioscience: A Culture of Diversity, Equity, Inclusion, and Belonging. At Kivu Bioscience, we are driven by our mission to develop groundbreaking therapies that advance oncology treatment and improve patients’ lives. Our success stems from the strength and diversity of our team, and we are deeply committed to creating an environment where every individual can thrive.
We foster a collaborative, inclusive culture built on intellectual curiosity, innovation, and a shared passion for making a difference. Our fast-paced environment encourages continuous learning, and we are fully invested in the recruitment, training, and professional growth of each team member.
Join Us
Kivu Bioscience is seeking motivated, dynamic individuals who are inspired to join our mission of advancing next-generation ADCs for oncology. If you are passionate about transforming cancer treatment and making a meaningful impact, we’d love to connect with you.
To be considered for a position at Kivu Bioscience, please send us a message using the button below.
Media
Human-Based Preclinical Models May Improve Toxicity Prediction in Oncology Development
At BIO International Convention 2026, Mohit Trikha, PhD, CEO of Kiva Bioscience, discussed why emerging human-based preclinical models may have their greatest impact in predicting drug toxicity and tolerability rather than replacing animal testing outright.
Can Organoids and Human-Based Models Improve Drug DevelopmentPredictability?
At the BIO International Convention 2026, oncology drug development expert Mohit Trikha, PhD, CEO, Kivu Bioscience, discusses the promise and limitations of organoids and other human-based preclinical models, emphasizing the need for stronger validation, cross-functional collaboration, and early regulatory engagement to improve clinical trial success rates.
Safety Is The Mantra In Kivu Bioscience’s ADC Trials For Solid Tumors
A conversation between Kivu Bioscience CEO Mo Trikha and Clinical Leader Executive Editor Abby Proch In acrowded antibody-drug conjugate (ADC) landscape, differentiation hinges on improving the fundamentalrisk–benefit equation.
Investors
Shaping the future of targeted oncology ADCs
We are commited to improving patient outcomes and treatment tolerability